Global Financial Private Client’s Alexion Pharmaceuticals ALXN Stock Holding History

Global Financial Private Client’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4	Closed	-$740	–	612
2021 Q2	$740	Hold	4	–	–	﹤0.01%	558
2021 Q1	$613	Hold	4	–	–	﹤0.01%	542
2020 Q4	$625	Buy	+4	New	+$514	﹤0.01%	519

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Global Financial Private Client's ALXN Position: Q3 2021 in Review

Global Financial Private Client sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4 shares — an estimated $740 sold.

Global Financial Private Client first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $740 in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Global Financial Private Client reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Global Financial Private Client sold 4 Alexion Pharmaceuticals shares in Q3 2021, an estimated $740.
Global Financial Private Client first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Global Financial Private Client's Alexion Pharmaceuticals position peaked at $740 in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Global Financial Private Client's 13F filing for Q3 2021, filed 16 May 2024.